University of Nebraska

Dean J Tuma

Thomas L McDonald

Geoffrey M Thiele

Michael F Sorrell

Lynell W Klassen

Harriet C Beckenhauer

Anthony J Barak

A novel protein adduct is disclosed which is associated with the presence of alcohol liver disease. The adduct is a hybrid product of malondialdehyde and acetaldehyde which act synergistically to bind hepatic proteins. The adduct is highly immunogenic and fluorescent. Methods of detection are also disclosed including monoclonal and polyclonal antibodies.

Acetaldehyde and malondialdehyde protein adducts as markers for alcohol liver disease

High fluorescence specific immune enhancing factor and methods of use

Acetaldehyde and malondialdehyde protein adducts

This invention encompasses pharmaceutical compositions in the dietary supplement for treating or preventing fatty infiltration, the first stage of cirrhosis of the liver comprising and administering of not less than 1500 mg of betaine per kg of body weight per day. Dietary supplementation of betaine was shown to completely protect against liver fatty infiltration in rats exposed to prolonged ethanol intake as well as carbon tetrachloride. Hepatic levels of SAM were also elevated, which suggests the mechanism for the protection of the liver.

Use of betaine as a hepatic generator of S-adenosylmethionine and as a

Growing community of inventors

Omaha, NE, United States of America

Dean J Tuma